RecruitingNot ApplicableNCT07085611

Neutralizing Power of Serum Antibodies - 2

Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)

Sponsor

Centre Hospitalier Régional d'Orléans

Enrollment

30 participants

Start Date

Aug 22, 2025

Study Type

INTERVENTIONAL

Conditions

COVID-19 Vaccination Mucosal Immunity Serum SARS-CoV-2 Viraemia Monkey Pox

Summary

Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Sample collection (blood and optional nasal swab) for people with covid-19, monkey pox, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSample collection (blood and optional nasal swab)

Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur